These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23382115)

  • 1. Human regulatory T cells do not suppress the antitumor immunity in the bone marrow: a role for bone marrow stromal cells in neutralizing regulatory T cells.
    Guichelaar T; Emmelot ME; Rozemuller H; Martini B; Groen RW; Storm G; Lokhorst HM; Martens AC; Mutis T
    Clin Cancer Res; 2013 Mar; 19(6):1467-75. PubMed ID: 23382115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice.
    Mutis T; van Rijn RS; Simonetti ER; Aarts-Riemens T; Emmelot ME; van Bloois L; Martens A; Verdonck LF; Ebeling SB
    Clin Cancer Res; 2006 Sep; 12(18):5520-5. PubMed ID: 17000688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice.
    Li Y; Chen HL; Bannick N; Henry M; Holm AN; Metwali A; Urban JF; Rothman PB; Weiner GJ; Blazar BR; Elliott DE; Ince MN
    J Immunol; 2015 Feb; 194(3):1011-20. PubMed ID: 25527786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.
    Kim BS; Nishikii H; Baker J; Pierini A; Schneidawind D; Pan Y; Beilhack A; Park CG; Negrin RS
    Blood; 2015 Jul; 126(4):546-57. PubMed ID: 26063163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease.
    Yang J; Ramadan A; Reichenbach DK; Loschi M; Zhang J; Griesenauer B; Liu H; Hippen KL; Blazar BR; Paczesny S
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30694220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.
    Tawara I; Koyama M; Liu C; Toubai T; Thomas D; Evers R; Chockley P; Nieves E; Sun Y; Lowler KP; Malter C; Nishimoto N; Hill GR; Reddy P
    Clin Cancer Res; 2011 Jan; 17(1):77-88. PubMed ID: 21047980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced flowcytometric analysis of regulatory T cells: CD127 downregulation early post stem cell transplantation and altered Treg/CD3(+)CD4(+)-ratio in severe GvHD or relapse.
    Bremm M; Huenecke S; Lehrnbecher T; Ponstingl E; Mueller R; Heinze A; Bug G; Quaiser A; Kapinsky M; Brehm C; Bader P; Schneider G; Klingebiel T; Koehl U
    J Immunol Methods; 2011 Oct; 373(1-2):36-44. PubMed ID: 21839739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model.
    Yang J; Fan H; Hao J; Ren Y; Chen L; Li G; Xie R; Yang Y; Qian K; Liu M
    Transfusion; 2012 Jun; 52(6):1333-47. PubMed ID: 22098312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-17 gene ablation does not impact Treg-mediated suppression of graft-versus-host disease after bone marrow transplantation.
    Colonna L; Florek M; Leveson-Gower DB; Sega EI; Baker J; Smith AT; Negrin RS
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1557-65. PubMed ID: 23921175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential T cell subsets and cytokine profile between steady-state and G-CSF-primed bone marrow and its association with graft-versus-host disease.
    León-Rodríguez E; Rivera-Franco MM; Gómez-Martín D; Romo-Tena J; Juárez-Vega G; Merayo-Chalico J; Alcocer-Varela J
    Leuk Res; 2017 Dec; 63():47-52. PubMed ID: 29101827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.
    Chen C; Cao J; Zeng L; Li Y; Wang D; Xu K
    Transplant Proc; 2011 Jun; 43(5):2041-8. PubMed ID: 21693322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype.
    Ali N; Flutter B; Sanchez Rodriguez R; Sharif-Paghaleh E; Barber LD; Lombardi G; Nestle FO
    PLoS One; 2012; 7(8):e44219. PubMed ID: 22937164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.
    Shin HJ; Baker J; Leveson-Gower DB; Smith AT; Sega EI; Negrin RS
    Blood; 2011 Aug; 118(8):2342-50. PubMed ID: 21734238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
    Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of graft-versus-host disease by intrabone marrow injection of donor T cells: involvement of bone marrow stromal cells.
    Miyake T; Inaba M; Fukui J; Ueda Y; Hosaka N; Kamiyama Y; Ikehara S
    Clin Exp Immunol; 2008 Apr; 152(1):153-62. PubMed ID: 18307515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solid Tumor-Induced Immune Regulation Alters the GvHD/GvT Paradigm after Allogenic Bone Marrow Transplantation.
    Dang N; Lin Y; Rutgeerts O; Sagaert X; Billiau AD; Waer M; Sprangers B
    Cancer Res; 2019 May; 79(10):2709-2721. PubMed ID: 30936086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.
    Sun K; Hsiao HH; Li M; Ames E; Bouchlaka M; Welniak LA; Hagino T; Jagdeo J; Pai CC; Chen M; Blazar BR; Abedi M; Murphy WJ
    J Immunol; 2012 Aug; 189(4):2033-42. PubMed ID: 22778394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of human regulatory T cells de novo with suppressive function prevent xenogeneic graft versus host disease.
    Qian X; Wang K; Wang X; Zheng SG; Lu L
    Int Immunopharmacol; 2011 May; 11(5):630-7. PubMed ID: 21147213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity.
    Beres AJ; Haribhai D; Chadwick AC; Gonyo PJ; Williams CB; Drobyski WR
    J Immunol; 2012 Jul; 189(1):464-74. PubMed ID: 22649199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.